CLINICAL TRIALS PROFILE FOR MARGENZA
✉ Email this page to a colleague
All Clinical Trials for MARGENZA
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT04425018 ↗ | MARGetuximab Or Trastuzumab (MARGOT) | Recruiting | MacroGenics | Phase 2 | 2020-07-13 | The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs. Drugs and Combinations used: - Paclitaxel, Pertzumab and Margetuximab (Margenza) - Paclitaxel, Pertzumab and Trastuzumab (Herceptin) |
NCT04425018 ↗ | MARGetuximab Or Trastuzumab (MARGOT) | Recruiting | Translational Breast Cancer Research Consortium | Phase 2 | 2020-07-13 | The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs. Drugs and Combinations used: - Paclitaxel, Pertzumab and Margetuximab (Margenza) - Paclitaxel, Pertzumab and Trastuzumab (Herceptin) |
NCT04425018 ↗ | MARGetuximab Or Trastuzumab (MARGOT) | Recruiting | Dana-Farber Cancer Institute | Phase 2 | 2020-07-13 | The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs. Drugs and Combinations used: - Paclitaxel, Pertzumab and Margetuximab (Margenza) - Paclitaxel, Pertzumab and Trastuzumab (Herceptin) |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MARGENZA
Condition Name
Clinical Trial Locations for MARGENZA
Trials by Country
Clinical Trial Progress for MARGENZA
Clinical Trial Phase
Clinical Trial Sponsors for MARGENZA
Sponsor Name